Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.44 |
| ▸ | CCR9 | P51686 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.37 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10022436 | 0.88 | BRPF1 (0.44) | ACSS2CYP11B2CYP11B1S1PR1CYP2A6 | |
| SCHEMBL10022420 | 0.80 | CDC7 (0.40) | CCR9BRPF1CDC7 | |
| SCHEMBL7491601 | 0.80 | CYP11B2 (0.46) | ACSS2CCR9CYP11B2CYP11B1S1PR1 | |
| SCHEMBL16168681 | 0.78 | CYP2A6 (0.47) | ACSS2CCR9CYP11B2CYP11B1S1PR1 | |
| SCHEMBL7489858 | 0.78 | SLC6A2 (0.36) | ACSS2CCR9CYP11B2CYP11B1S1PR1 | |
| SCHEMBL7443187 | 0.78 | SLC6A2 (0.36) | ACSS2CCR9CYP11B2CYP11B1S1PR1 | |
| SCHEMBL10022666 | 0.77 | CCR9 (0.65) | ACSS2CCR9CYP11B2CYP11B1 | |
| SCHEMBL21907095 | 0.76 | ACSS2 (0.41) | ACSS2CCR9PTGER4 | |
| SCHEMBL7435149 | 0.76 | ACSS2 (0.44) | ACSS2CCR9CYP11B2CYP11B1CYP2A6 | |
| SCHEMBL7220183 | 0.76 | CYP11B2 (0.43) | ACSS2CCR9CYP11B2CYP11B1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165322-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | ACSS2 1356/4885CCR9 2200/4885CYP11B2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.